CALGB 140503 (Alliance): Phase III Trial of Lobar or Sublobar Resection for Peripheral Clinical Stage IA NSCLC With Tumor Size ≤2 cm

August 6-9, 2022; Vienna, Austria
Sublobar resection resulted in noninferior DFS and OS compared with lobectomy for patients with peripheral cT1aN0 NSCLC and tumor size ≤2 cm without metastases to major hilar and mediastinal lymph nodes.
Format: Microsoft PowerPoint (.ppt)
File Size: 191 KB
Released: August 19, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Genentech, a member of the Roche Group
Merck Sharp & Dohme Corp.
Turning Point Therapeutics, Inc.

Related Content

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered lung and thyroid cancer

person default Saad A. Khan, MD Sandip P. Patel, MD Released: November 17, 2022

Downloadable resource on the role of RET and NTRK aberrations in lung and thyroid cancer, including guidance on testing and review of the clinical data on RET and NTRK inhibitor therapy for these diseases, from Clinical Care Options (CCO)

Released: November 14, 2022

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD person default Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: November 14, 2022 Expired: November 13, 2023

Download this slideset for an overview of key data on immunotherapy in early-stage resectable and stage III unresectable NSCLC, from Clinical Care Options (CCO)

Zofia Piotrowska, MD, MHS Released: November 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings